Litcius/Paper detail

Anti–IL-23 treatment with tildrakizumab can be effective in omalizumab-refractory chronic spontaneous urticaria: A case series

Hanna Bonnekoh, Lea Kiefer, Thomas Buttgereit, Pavel Kolkhir, Marie Lütke-Eversloh, Jörg Scheffel, Marcus Maurer, Martin Metz

2023The Journal of Allergy and Clinical Immunology In Practice14 citationsDOI

Topics & Concepts

OmalizumabMedicineRefractory (planetary science)Chronic urticariaDermatologyMonoclonalImmunologyAntibodyMonoclonal antibodyImmunoglobulin EPhysicsAstrobiologyUrticaria and Related ConditionsDermatology and Skin DiseasesAutoimmune Bullous Skin Diseases
Anti–IL-23 treatment with tildrakizumab can be effective in omalizumab-refractory chronic spontaneous urticaria: A case series | Litcius